London, December 13, 2022 /PRNewswire/ — Abingworth, a leading international life sciences investment group, announces the following appointments: Joy Ghosh, a PhD as Managing Director.Joy will be the base of the company Boston, Massachusetts We work with our transatlantic team to identify new investment opportunities and support existing investments in innovative private and public companies, including those focused on clinical co-development.
Joy brings to Abingworth more than 15 years of experience in life sciences investment and portfolio company management, as well as corporate strategy and drug development. He joined from his Eventide Asset Management as his portfolio manager, responsible for a portfolio of innovation-focused public and private healthcare and life sciences companies. Prior to Eventide, Joy was Vice President of Bain Capital. During his tenure at both companies, he completed 24 of his personal investments and served on the boards of several companies.
Early in his career, Joy held senior positions in business development and corporate strategy at Biogen and was a project team leader at the Novartis Institutes for BioMedical Research (NIBR). He holds a PhD in Structural Biology and Neuroscience. University of Washington I have a bachelor’s degree in biochemistry from. University of Texas.
Joy Ghosh Said The company has a strong team, an impressive track record and a truly exciting future since joining Carlyle earlier this year. Creating a powerful combination that has the potential to support innovative companies moving forward along the entire continuum of discovery, development and commercialization.This approach will bring transformative new treatments to patients. We are confident that it will improve the possibilities and speed.”
Managing Partner and Chief Investment Officer Bali Muraridar said: “We are thrilled to welcome Joy to the Abingworth team. His extensive experience in investing, along with his expertise in strategy and drug development, will enable us to source and develop exciting life sciences opportunities at all stages of development. It further enhances our ability to assess, invest and manage.”
Abingworth is a transatlantic life sciences investment firm and part of Carlyle (NASDAQ: CG), a global investment firm. Abingworth helps transform cutting-edge science into new medicines by providing capital and expertise to leading management teams that build world-class companies. Since 1973, Abingworth has invested in more than 180 of her life sciences companies, 49M&As and over 70 IPOs. Our therapeutic-focused investments fall into three categories: seed and early-stage, development-stage, and clinical co-development. Abingworth maintains a team of experienced professionals in its US offices to support its portfolio companies. London, Menlo Park (California), When boston.
Managing Partner and Chief Investment Officer
Phone: +44 (0)20 7534 1500
Mark Swallow Also Eleanor ParkinMedistrava Consulting
Phone: +44 (0)203 928 6900
Email: [email protected]